This session follows the real-world journey of a patient with advanced heart failure whose condition progresses despite guideline-directed therapy. Presented by three expert nurse speakers, the session highlights the pivotal role nurses and allied health professionals play at every stage of the transplant continuum.
Starting with an in-depth patient case, the seminar explores how nurses identify therapy barriers, engage in patient-centered problem-solving, and support adherence when medical therapy fails. Faculty will then guide learners through the transition to transplant, emphasizing nursing responsibilities in evaluation, education, communication, and cross-team coordination. Post-transplant care is examined through the lens of the nurse coordinator’s role in surveillance, complication prevention, medication management, and long-term patient support.
Describe the clinical progression and decision-making pathway for an advanced heart failure patient who does not respond to medical therapy.
Identify common therapy barriers faced by patients and explain how nurses can address them through communication, education, and interdisciplinary coordination.
Explain the role of nurses in the heart transplant process, including pre-transplant evaluation, patient preparation, and transitional support.
Discuss key responsibilities of nurse coordinators in post-transplant care, including monitoring, medication management, complication prevention, and patient advocacy.
Apply evidence-based nursing strategies to improve outcomes and enhance continuity of care across the transplant journey.
Faculty:
Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:
The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:
Megan Fraser, DNP, NP-C, CHFN, FHFSA, HF-Cert – Consultant: Novo Nordisk; Advisory Panel: American Heart Association
Off-Label DisclosureThis CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.
Laura Peters, FNP, FHFSA, HF-Cert
Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
In support of improving patient care, this activity is jointly provided by the Heart Failure Society of America (HFSA) and the International Society for Heart and Lung Transplantation (ISHLT). The Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this educational activity for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum of 0.50 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
The Heart Failure Society of America has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. As a designated Approved Provider by the American Board for Transplant Certification (ABTC), the International Society for Heart and Lung Transplantation grants up to 2.25 Category 1 Continuing Education Points for Transplant Coordinators (CEPTCs) for this offering. CEPTC Approval Number: 221-32.This activity, as part of the bundle, offers 0.50 CEPTCs
Successful completion of this activity includes the completion of the post-course evaluation.